Systemic Psoriasis Therapeutics Market

The Report “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 – Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth″ by GBI Research is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 – Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth ″ in subject line and your contact details to purchase this report or get your questions answered.

The collection of ‘Dermatology therapeutic’ market research reports has a new addition of “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 – Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth” on RnRMarketResearch.com. The Latest pharma Research report “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth”. The systemic psoriasis market is forecast to grow substantially over the forecast period from $5.0 billion in 2013 to $10.4 billion in 2020, across the eight major markets. This growth will be driven by a rising treatment population and the continued uptake of biologics.

Request a sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=148417 .

Biologics will continue to drive market growth despite leading brands Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab) losing patent protection in most of the major markets over the forecast period. Although the market will suffer revenue losses as a result of sales erosion from biosimilar competitors, this will be offset by the emergence of novel therapies. Most notably, these include monoclonal antibodies secukinumab, ixekizumab and brodalumab, which are currently being developed by Alcon (Novartis subsidiary), Eli Lilly and Amgen, respectively.

Scope

• An introduction to psoriasis, which includes symptoms, epidemiology, etiology, pathophysiology, diagnosis and treatment
•  Analysis of the major systemic therapies in the current psoriasis marketed landscape
• Analysis of the pipeline for psoriasis, which includes a breakdown of pipeline molecules by phase of development, molecule type, molecular target and novelty. Psoriasis clinical trials are analyzed by size, duration and failure rates, and a comparative analysis of the most promising systemic pipeline molecules is also provided.
•  Forecast projections for the systemic psoriasis market to 2020. Analysis is provided for the global market and each of the eight major markets. The forecast incorporates projected, low and high variance scenarios based on treatment usage patterns and annual therapy costs in each of the major markets.
•   Analysis of strategic consolidations, including co-development and licensing deals, within the psoriasis indication

 Complete report is available @ http://www.rnrmarketresearch.com/systemic-psoriasis-therapeutics-in-major-developed-markets-to-2020-continued-uptake-of-biologics-and-novel-pipeline-drugs-to-drive-growth-market-report.html . Read more on “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 – Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth” report below.

Reasons to buy

• Understand the current systemic psoriasis marketed products landscape and recognize the dominant therapeutic agents and pharmaceutical players involved
• Identify trends and developments within the psoriasis pipeline and consider how the future competitive environment will be impacted
•   Consider market opportunities and potential risks by examining the psoriasis clinical trial landscape in relation to industry averages
• Observe projections for treatment usage patterns, annual therapy costs and market growth in the eight major markets and understand reasons for variance in projected patterns of growth in the eight major markets

Table of Contents

1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7

2 Introduction 8
2.1 Overview 8
2.2 Epidemiology 9
2.3 Etiology, Co-morbidities and Risk Factors 10
2.3.1 Genetics 10
2.3.2 Psoriatic Arthritis 10
2.3.3 Mental Health Disorders 11
2.3.4 Metabolic Syndrome, Smoking, Diet and Alcohol Consumption 11
2.3.5 Infections 11
2.3.6 Köebner Phenomenon 12
2.3.7 Other Immune-mediated Diseases 12
2.4 Pathophysiology 12
2.5 Diagnosis 13
2.6 Treatment Options 13
2.6.1 Pharmacological Therapies 14
2.6.2 Non-pharmacological Therapies 15
2.6.3 Combination and Rotational Therapies 15
2.6.4 Quality of Life Assessments 16
2.7 Summary 16